Erik T. Engelson insider trades: Lucira Health (LHDX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Erik reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 3, 2023 | LHDX | ↓ Sell | 634,666 | $1.04 | $657K | Direct | Mar 13, 2023 (10d) |
| Sep 15, 2022 | LHDX | ↑ Buy | 20,000 | $1.82 | $36K | Direct | Sep 19, 2022 (4d) |
| Jun 16, 2022 | LHDX | ↑ Buy | 10,000 | $1.49 | $15K | Direct | Jun 17, 2022 (1d) |
| Mar 15, 2022 | LHDX | ↑ Buy | 30,000 | $3.00 | $90K | Direct | Mar 16, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Erik T. Engelson's insider trades
Erik T. Engelson is President and Chief Executive at Lucira Health (LHDX). Since Mar 15, 2022, Erik has reported 3 open-market purchases worth $141K and 1 sale worth $657K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (1 filing), conversions (1 filing), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LHDX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.